Next Generation Menin Inhibitor
Best-in-class menin inhibitor addressing resistance in Acute Myeloid Leukemia
Other · OtherCompany source
Company profile
About Charm Therapeutics
CHARM Therapeutics is a biotechnology company focused on delivering transformational medicines through advanced understanding of protein-ligand interactions. Founded by leaders with proven track records in AI and drug discovery, CHARM is developing a next-generation menin inhibitor for the treatment of Acute Myeloid Leukemia (AML). Unlike traditional AML therapies that attempt to kill leukemic cells, CHARM's approach focuses on reprogramming them by preventing the interaction that keeps them cancerous. The company has designed structurally optimized inhibitors that are highly potent and bind precisely within the KMT2A interface on menin. CHARM's best-in-class menin inhibitor is specifically engineered to address resistance mechanisms observed with first-generation menin approaches, with the goal of delivering durable treatment outcomes to AML patients. The company is advancing its lead candidate into clinical trials, leveraging AI-driven drug discovery capabilities to transform patient outcomes in hematologic malignancies.
Company description Charm Therapeutics official website
Primary marketDrug Discovery & Development
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Charm Therapeutics?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Acute Myeloid Leukemia (AML)
- Hematologic malignancies
Who it serves
- Clinical research organizations
- Healthcare providers
- Pharma
Deployment & integration
Other deployment with recorded integration context.
Geographic context
MarketsUnited Kingdom
Company sourceOfficial website
Company milestones
Platform expansion
Advancing next generation menin inhibitor into clinical trials
Partnerships
Recorded partners
No partners are currently listed.
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
AI-assisted delivery of novel covalent WRN inhibitors from a non-covalent fragment screen.Bioorganic & medicinal chemistry letters · Feb 1, 2026
Structural insights into WRN helicase reveal conformational states and opportunities for MSI-H cancer drug discovery.Communications biology · Jan 28, 2026
Boltz-1 Democratizing Biomolecular Interaction Modeling.bioRxiv : the preprint server for biology · May 6, 2025
SARS-CoV-2 Mpro responds to oxidation by forming disulfide and NOS/SONOS bonds.Nature communications · May 7, 2024
Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors.Science (New York, N.Y.) · Nov 10, 2023
Escherichia coli DNA repair helicase Lhr is also a uracil-DNA glycosylase.Molecular microbiology · Aug 1, 2023
Clinical validation
Clinical-trial records
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AMLNCT07751991 · Sponsor · RECRUITING
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Addresses resistance to first-generation menin inhibitors
Next-generation menin inhibitor design
Highly potent binding within KMT2A interface on menin
Structurally optimized inhibitors
Durable treatment outcomes
AML patient treatment
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Charm Therapeutics
Recent articles published on Charm Therapeutics's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Drug Discovery & Development
Companies using AI, machine learning, or computational biology to discover new drug candidates, identify drug targets, predict drug efficacy, or accelerate pharmaceutical development. Includes both small molecule and biologics development, precision oncology drug discovery, and AI-driven target identification and molecule design.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.